Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Recipient : ALMATICA PHARMA INC
Deal Size : $38.5 million
Deal Type : Acquisition
Bora Acquires Six US Brand Product Licenses, Rights
Details : Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Brand Name : Zestril
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 18, 2023
Lead Product(s) : Lisinopril
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Recipient : ALMATICA PHARMA INC
Deal Size : $38.5 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
